» Articles » PMID: 29463768

Ethical Implications of Excessive Cluster Sizes in Cluster Randomised Trials

Overview
Journal BMJ Qual Saf
Specialty Health Services
Date 2018 Feb 22
PMID 29463768
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The cluster randomised trial (CRT) is commonly used in healthcare research. It is the gold-standard study design for evaluating healthcare policy interventions. A key characteristic of this design is that as more participants are included, in a fixed number of clusters, the increase in achievable power will level off. CRTs with cluster sizes that exceed the point of levelling-off will have excessive numbers of participants, even if they do not achieve nominal levels of power. Excessively large cluster sizes may have ethical implications due to exposing trial participants unnecessarily to the burdens of both participating in the trial and the potential risks of harm associated with the intervention. We explore these issues through the use of two case studies. Where data are routinely collected, available at minimum cost and the intervention poses low risk, the ethical implications of excessively large cluster sizes are likely to be low (case study 1). However, to maximise the social benefit of the study, identification of excessive cluster sizes can allow for prespecified and fully powered secondary analyses. In the second case study, while there is no burden through trial participation (because the outcome data are routinely collected and non-identifiable), the intervention might be considered to pose some indirect risk to patients and risks to the healthcare workers. In this case study it is therefore important that the inclusion of excessively large cluster sizes is justifiable on other grounds (perhaps to show sustainability). In any randomised controlled trial, including evaluations of health policy interventions, it is important to minimise the burdens and risks to participants. Funders, researchers and research ethics committees should be aware of the ethical issues of excessively large cluster sizes in cluster trials.

Citing Articles

Enhancing insight into regional differences: hierarchical linear models in multiregional clinical trials.

Kim J, Kang S BMC Med Res Methodol. 2025; 25(1):69.

PMID: 40075291 PMC: 11900657. DOI: 10.1186/s12874-025-02479-4.


A systematic review of sample size estimation accuracy on power in malaria cluster randomised trials measuring epidemiological outcomes.

Biggs J, Challenger J, Hellewell J, Churcher T, Cook J BMC Med Res Methodol. 2024; 24(1):238.

PMID: 39407101 PMC: 11476958. DOI: 10.1186/s12874-024-02361-9.


Establishing the safety of selective digestive decontamination within the ICU population: a bridge too far?.

Hurley J Trials. 2023; 24(1):337.

PMID: 37198636 PMC: 10189709. DOI: 10.1186/s13063-023-07356-3.


Reporting of and explanations for under-recruitment and over-recruitment in pragmatic trials: a secondary analysis of a database of primary trial reports published from 2014 to 2019.

Nevins P, Nicholls S, Ouyang Y, Carroll K, Hemming K, Weijer C BMJ Open. 2023; 12(12):e067656.

PMID: 36600344 PMC: 9743401. DOI: 10.1136/bmjopen-2022-067656.


Empowering local research ethics review of antibacterial mass administration research.

Sewankambo N, Kutyabami P Infect Dis Poverty. 2022; 11(1):103.

PMID: 36171611 PMC: 9516823. DOI: 10.1186/s40249-022-01031-6.


References
1.
Altman D . Statistics and ethics in medical research: III How large a sample?. Br Med J. 1980; 281(6251):1336-8. PMC: 1714734. DOI: 10.1136/bmj.281.6251.1336. View

2.
Hemming K, Eldridge S, Forbes G, Weijer C, Taljaard M . How to design efficient cluster randomised trials. BMJ. 2017; 358:j3064. PMC: 5508848. DOI: 10.1136/bmj.j3064. View

3.
Peto R, Collins R, Gray R . Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol. 1995; 48(1):23-40. DOI: 10.1016/0895-4356(94)00150-o. View

4.
Charles P, Giraudeau B, Dechartres A, Baron G, Ravaud P . Reporting of sample size calculation in randomised controlled trials: review. BMJ. 2009; 338:b1732. PMC: 2680945. DOI: 10.1136/bmj.b1732. View

5.
Button K, Ioannidis J, Mokrysz C, Nosek B, Flint J, Robinson E . Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013; 14(5):365-76. DOI: 10.1038/nrn3475. View